Therapeutic Inertia in the Outpatient Management of Dyslipidemia in Patients With Ischemic Heart Disease. The Inertia Study

Pablo Lázaro,[a] Nekane Murga,[b] Dolores Aguilar,[a] and Miguel A. Hernández-Presa[c] on behalf of the INERTIA Study investigators

[a]Técnicas Avanzadas de Investigación en Servicios de Salud, Madrid, Spain
[b]Servicio de Cardiología, Hospital Civil de Basurto, Bilbao, Spain
[c]Unidad Médica, Pfizer SA, Madrid, Spain

Introduction and objectives. Studies indicate that dyslipidemia is undertreated. Numerous systematic reviews have shown that, even when therapeutic targets set by clinical practice guidelines have not been met, treatment remains unchanged despite the availability of alternatives approaches. The result is increased morbidity and mortality. Our aims were to investigate this phenomenon, known as therapeutic inertia, in patients with dyslipidemia and ischemic heart disease, and to determine its possible causes.

Methods. Design: national, multicenter, observational study of data obtained from physicians by questionnaire and from the clinical records of patients with ischemic heart disease. Main variable: therapeutic inertia during a consultation, defined as treatment remaining the same despite a change being indicated (e.g. low-density lipoprotein cholesterol >100 mg/dl or >70 mg/dl in diabetics). Covariates: physician, patient and consultation characteristics. Statistical analysis: multivariate logistic regression analysis of factors associated with therapeutic inertia during a consultation.

Results. Overall, 43% of consultations involved therapeutic inertia, and an association with coronary risk factors, including diabetes, did not result in a change in treatment. Therapeutic inertia occurred more frequently when there was a long time between the diagnosis and treatment of dyslipidemia and that of ischemic heart disease. Undertreatment was particularly common in women despite a greater overall risk. The more experienced physicians treated younger patients more appropriately. Clinical practice was improved by educational sessions at conferences.

Conclusions. Therapeutic inertia was common in patients with chronic ischemic heart disease and dyslipidemia, irrespective of overall cardiovascular risk. Factors associated with the patient, disease and physician had an influence.

Key words: *Therapeutic inertia. Lipid management. Ischemic heart disease.*

Therapeutic Inertia in the Outpatient Management of Dyslipidemia in Patients With Ischemic Heart Disease. The Inertia Study

Introducción y objetivos. Se ha descrito infratratamiento de las dislipemias. En sucesivas revisiones clínicas, aunque no se alcancen los objetivos terapéuticos marcados por las guías de práctica clínica, no se modifican los tratamientos a pesar de que se dispone de alternativas terapéuticas. Esta actitud, conocida como inercia terapéutica, produce un incremento de la morbimortalidad. Pretendemos medirla en pacientes con dislipemia y cardiopatía isquémica y analizar sus posibles causas.

Métodos. Diseño: estudio observacional multicéntrico nacional, con recogida de datos mediante cuestionario al médico y revisión de historias clínicas de pacientes con cardiopatía isquémica. Variable principal: inercia terapéutica en la visita, sin modificación de medicación a pesar de indicación de cambio (colesterol de las lipoproteínas de baja densidad > 100 mg/dl o > 70 mg/dl en diabéticos). Covariables: del médico, del paciente y de la visita. Análisis estadístico: estudio multivariable de regresión logística de los factores asociados a la inercia terapéutica en la visita.

Resultados. En un 43% de las visitas se actúa con inercia terapéutica; la asociación con factores de riesgo coronario, incluida la diabetes, no motiva cambio del tratamiento. La inercia terapéutica está favorecida por un mayor tiempo desde el diagnóstico y el tratamiento de la dislipemia y de la cardiopatía isquémica. Las mujeres están especialmente infratratadas a pesar de un mayor riesgo total. Los médicos más experimentados tratan mejor a los pacientes más jóvenes. La formación en congresos mejora la práctica clínica.

Conclusiones. Elevada inercia terapéutica en pacientes con cardiopatía isquémica crónica y dislipemia, independientemente del riesgo cardiovascular total. Intervienen factores dependientes del paciente, de la enfermedad y del médico.

Palabras clave: *Inercia terapéutica. Manejo de lípidos. Cardiopatía isquémica.*

ABBREVIATION

COCS: Clinical and Outpatient Cardiology
  Section
CPG: clinical practice guideline
HDL-C: high-density lipoprotein cholesterol
LDL-C: low-density lipoprotein cholesterol
SD: standard deviation
TI: therapeutic inertia

INTRODUCTION

Therapeutic Inertia (TI) is defined as physicians' failure to begin or intensify indicated treatment.[1-3] TI is common in the treatment of chronic diseases, such as diabetes, hypercholesterolemia and hypertension, especially during asymptomatic phases.[4-6] Among the causes of TI described are physician overestimation of the degree of adherence to clinical practice guidelines (CPG), a false impression of good control of the disease, perception of the patient's poor adherence and lack of training and organisation.[1] And other physician dependent factors such as age, sex, years of training or training and research activities during the last years seem to play an important role in the existence of TI.[7] TI has also been described associated with a patient's clinical situation at the time of consultation (laboratory or clinical parameters or treatment received), and to factors such as age, race, sex or patient comorbidity.[3,8-13] Although the results of these studies are not always conclusive. Concretely, studies of lipid management therapeutic inertia have described associations with sex[14,15] and age.[9,16]

There is a clearly established association between a decrease of low density lipoprotein bound cholesterol (LDL-C) and risk of coronary death.[17] According to the latest report of the National Cholesterol Education Program[18] a therapeutic target of LDL-C <100 mg/dL is recommended in patients with ischaemic cardiopathy and <70 mg/dL if they are diabetic.

There is evidence of low compliance with the GPC recommendations for lipid management, both in primary and secondary prevention.[13,19-22] For example, in the USA, it was found that less than 33% of patients admitted for myocardial infarction were receiving lipid reducing treatment on discharge[19] and that with an LDL-C >160 mg/dL, the probability that the physicians would adjust the statin dose was less than 30%.[20] In the United Kingdom, a population study found that 35% of men and 20% women receiving lipid reducing treatment achieve the recommended therapeutic targets.[21]

In Spain only 13% of patients with dyslipidaemia achieved the therapeutic target of LDL-C during initial treatment with lipid reducing drugs, another 13% achieved the target after changes in treatment, and 74% did not achieve the target after 3 years of follow-up. Paradoxically, the patients in which therapeutic target was least achieved were those that obtained greatest benefit from lipid reducing treatment.[23]

TI in the management of lipids in chronic ischaemic cardiopathy has not been studied. This study has the aim of increasing knowledge of TI in outpatient management of dyslipidaemia in patients with chronic ischaemic cardiopathy in Spain, in addition to establishing determinant or associated factors. This knowledge is basic to understand this phenomenon better and, therefore, to design strategies to decrease TI.

METHODS

Design

Epidemiological, observational, retrospective and multicentric national study, performed by means of reviewing clinical histories and providing questionnaires to physicians.

Instrument

Based on the factors associated with TI described in previous studies,[1-20] the authors designed a questionnaire to collect the data corresponding to three information blocks (physicians, patients and visits).

Patient Inclusion Criteria

a) 18 years of age or over; *b)* diagnosis of dyslipidaemia with drug treatment during the previous 24 months; *c)* diagnosis of ischaemic cardiopathy; *d)* follow-up by cardiologist "both of external and ambulatory consultations" during the last 24 months; *e)* minimum of 3 visits during that period with a register of the patient's lipid profile; and *f)* with LDL-C >100 mg/dL, in at least one of the visits.

Predetermination of Sample Size

To detect differences of 4% (eg, 50%-54%) in visit estimations, in a situation of maximum lack of determination (p=q=0.5), with a precision (alpha) of

TABLE 1. Classification of Therapeutic Inertia Based on LDL-C Levels and the Presence of Other Risk Factors

LDL-C, mg/dL	Risk Factors		
	Non Smoker and Non Diabetic	Smoker or Diabetic With No Other RF	Smoker+HT or Diabetes+Smoker or Diabetes+HT
≥70-<100	NA	TI	High TI
≥100	TI	High TI	Very high TI

HT indicates hypertension; LDL-C, low density lipoproteins cholesterol; NA, not applicable (according to the definition of TI used); TI, therapeutic inertia.

.05 and a statistical power (1-beta) of .8, 4770 visits are required. Considering 3 visits per patient (data from 1590 patients are necessary), and 10 patients per physician, 159 physicians must participate.

Sample Taking

The sample was taken from the clinical registers of a non-randomised sample of cardiologists consultations throughout Spain. One hundred and fifty-five cardiologists participated (76.7% carried out their activity in external or ambulatory hierarchical offices in tertiary hospitals, 14.7% in consulting offices in regional hospitals, and the rest were not hierarchical). Each physician carried out a review (retrospective) of the clinical histories of the 10 first patients with a diagnosis of ischaemic cardiopathy and dyslipidaemia that complied with the inclusion criteria in November 2008 and answered the questionnaire.

Definition of Valid Visit

We considered that valid visits were those that included LDL-C measurement and complete treatment data (drug, dose, and adverse effects).

Main Variable

Visits were taken as analyses units, and therefore the main variable is TI of a visit. There was considered to be TI when no change was made in medication, when it should have been. It was defined that a change in medication was necessary when LDL-C >100 mg/dL or >70 mg/dL in diabetic patients.[18] TI was studied for those visits that complied with the following criteria: *a)* a change of medication was indicated; *b)* it was possible to change medication (there would not be this possibility in patients treated with the most potent statin at its maximum dosage, which at the time of the study was atorvastatin 80 mg/day); and *c)* lipid lowering treatment has not caused any adverse effects on the patient. The severity of a visit's TI has been classified as TI, high TI, or very high TI according to LDL-C values and the patient's risk factors. Diabetes and smoking have been weighted to a greater degree, since they are the coronary risk factors with the highest adjusted relative risk for the Spanish population, in men and women, respectively[24] (Table 1).

Variables

Of the physician: profile (sex, years of experience in their specialty); training (general training courses and specific courses on dyslipidaemia, number of congresses attended in the last two years and hours per year of training at their work centre); type estimated by the physician, of patients attending their consulting offices (mean number of patients/week, percentage of dyslipidaemia among their patients); physicians' opinion on the existence of undertreatment of lipids in ischaemic cardiopathy (overloaded care system, ignorance of guidelines, lack of confidence in trial results, fear of medication side effects, lack of protocols and organisational aspects); management of lipid levels in collaboration with primary care services (a target value is set and the patient is sent to primary care for adjustment of this value).

Of the patient: sociodemographic data (sex, age, education, weight, and height); disease data: (date of diagnosis of ischaemic cardiopathy, of dyslipidaemia and of beginning of dyslipidaemia drug treatment); cardiovascular risk factors (diabetes, arterial hypertension, stroke, smoking; lifestyle, exercise, and diet).

Of the visit: date; lipid profile (total cholesterol, HDL-C, LDL-C, triglycerides); lipid lowering treatment on arrival for consultation (active ingredients and dosage); side effects of the treatment; change of medication on this visit and lipid lowering treatment on leaving consultation (active ingredients and dosage).

Statistical Analysis

Description of physician, patient, and visit variables. Recoding of variables: treatment with statins on each visit (yes/no) and number of lipid

Figure 1. Diagram of the method used for taking the final valid simple.
[a]IC: Patient inclusion criteria.
[b]LDL-c: Visit with low density lipoprotein cholesterol values available.
[c]Criteria for treatment change: LDL-c > 100 without Diabetes, or LDL-c > 70 with Diabetes: With no [sic]
With no adverse side effects to current lipid lowering medication.

lowering drugs. Calculation and description of TI and its severity on the visit (N and %). Study of the univariate association between TI and the visit and the independent variables described using a χ^2 test and OR calculation without adjusting. Study of factors associated with the TI of the visit, using a multivariate logistical regression model. The hypothesis contrasts were performed using 2 tails, for a level of significance of $\alpha = .05$.

RESULTS

Most participating physicians were men with experience, the data on their characteristics and opinions can be seen in Table 2.

In Tables 3 and 4 we summarise the characteristics of the population studied and their lipid profile. As expected, there is a predominance of men, of high mean age, with obesity or overweight, former smokers with a high prevalence of hypertension and diabetes. Risk factors were more frequent in women. Seven out of 10 followed a lipid lowering diet and less than one third carried out regular exercise. In 76.3% of visits LDL-C was above the target value recommended in the guidelines.

In Figure 1 it is possible to see the sampling of valid visits for the study. In 92.1% of visits with complete data, patients received statin treatment,

with the following order of frequency: atorvastatin (58.6%), simvastatin (22.8%), pravastatin (9.8%), and lovastatin (1.9%). Globally, there were treatment changes in 46.7% of visits and lipid lowering treatment adverse effects were seen in 2.9%. In 8.3% of visits in which the therapeutic target for LDL-C was not achieved, the patient was receiving the maximum lipid lowering dose (atorvastatin 80 mg/day). Lastly, the TI study of the visit was performed for 3,824 visits with medication change criteria. In 1636 (42.8%) of the visits there was TI, considered in 29.5% as high and in 28.9% as very high (Table 5).

In the univariate analysis, significant associations were found that disappeared when the multivariate model was adjusted. This was the case with the following variables: Triglycerides (lower levels of triglycerides, higher TI); patient age (greater age, greater TI), patients of 55-75 years of age in relation to those <55 years of age had an OR=1.35 (95% CI, 1.14-1.66) and those >75 years of age an OR=1.66 (95% CI, 1.33-2.10). Following a lipid lowering diet in comparison with not following a lipid lowering diet had an OR=1.17(1.02-1.35); not receiving lipid lowering treatment in comparison with receiving 2 or more drugs is a protective factor (OR=0.3; 95% CI, 0.2-0.5), whereas receiving only one drug is a risk factor (OR=1.3; 95% CI, 1.1-1.6); number of patients a week ≥50 in comparison with = 50 had an

TABLE 2. **Physician Characteristics**

	No. (%)
Sex (n=149)	
Male	123 (82.6)
Female	26 (17.4)
Years of experience in the speciality (n=147; mean: 18.6 years; SD: 9.7)	
≤10	42 (28.6)
>10 and ≤20	38 (25.9)
>20	67 (45.6)
Training coursed during the last 2 years (n=144; mean: 5.2 courses; SD: 4.0)	
0	4 (2.8)
1 to 3	50 (34.7)
4 to 6	54 (37.5)
≥7	36 (25.0)
Number of Congresses attended during the last 2 years (n=148; mean: 5.5 Congresses; SD: 3.9)	
0 to 3	46 (31.1)
4 to 6	66 (44.6)
≥7	36 (24.3)
Annual training hours at own work centre (n=121; mean: 56.9 hours; SD: 100.2)	41 (33.9)
0 to 9	
10 to 49	38 (31.4)
≥50	42 (34.7)
Number of training courses on dyslipidaemia attended during the last 2 years (n=139; mean: 2.7 courses; SD: 8.3)	
0	30 (21.6)
1 to 2	80 (57.6)
≥3	29 (20.9)
Mean number of patients per week (n=147; mean: 96.7 patients/week; SD: 63.0)	
<60	40 (27.2)
60 to 100	67 (45.6)
>100	40 (27.2)
According to physicians: percentage of their patients with dyslipidaemia (n=147)	
≤25	16 (10.3)
>25 to ≤50	64 (43.8)
>50 to ≤75	42 (28.8)
>75	25 (17.1)
According to physicians: percentage of dyslipidaemic patients that comply with treatment (n=142)	
≤25	4 (2.8)
>25 to ≤50	24 (16.9)
>50 to ≤75	41 (28.9)
>75	73 (51.4)
Sets therapeutic target values and refers patient to primary care for adjustment (n=151)	
Yes	67 (44.4)
Believes that dyslipidaemia in patients with IC is undertreated (n=147)	
Yes	122 (83.0)
Opinion on causes of undertreatment of dyslipidaemia (n=122) (multiple-answers)	
Care overload	75 (61.5)
Ignorance of CPG	47 (38.5)
Lack of confidence in EC	6 (4.9)
Fear of side effects	27 (22.1)
Lack of protocols	17 (13.9)
Organisational aspects	25 (20.5)
High expenditure	6 (4.9)
Patient non-compliance	5 (4.1)
Therapeutic inertia	1 (0.8)

CPG indicates clinical practice guidelines; CT, clinical trials; IC, ischaemic cardiopathy; n: number of valid observations; SD: standard deviation.

OR=0.79 (95% CI, 0.66-0.96); having received 3 or more courses on dyslipidaemia in comparison with less than 3, had an OR=0.78 (95% CI, 0.66-0.92)

The OR of the raw data on the association between the other significantly associated variables in the univariate analysis can be seen in Table 6.

TABLE 3. Patient Characteristics

	No. (%)
Sex (n=1444)	
Male	1016 (70.4)
Female	428 (29.6)
Age in years (n=1,357; Mean: 65.3 years; SD: 10.1)	
≤55	234 (17.2)
>55 and ≤65	423 (31.2)
>65 and ≤75	462 (34.0)
>75	238 (17.5)
Level of education (n=1428)	
No education	291 (20.4)
Complete primary	544 (38.1)
Secondary	368 (25.8)
Diploma/University	225 (15.8)
Weight (n=1413; Mean BMI: 28.6; SD: 3.9)	
Low/normal weight	204 (14.4)
Overweight	784 (55.5)
Obesity	425 (30.1)
Years of diagnosed IC (n=1381; Mean: 6.1 years; SD: 5.3)	
<5	782 (56.6)
>5 and ≤10	403 (29.2)
>10	196 (14.2)
Years of diagnosed dyslipidaemia (n=1369; Mean: 7.2 years; SD: 5.7)	
≤5	619 (45.2)
>5 and ≤10	473 (34.6)
>10	277 (20.2)
Years of dyslipidaemia under treatment (n=1324; Mean: 6.4 years; SD: 5.1)	
≤5	692 (52.3)
>5 and ≤10	420 (31.7)
>10	212 (16.0)
Cardiovascular risk factors	
Hombres (n=1016)	
Diabetes	361 (35.5)
Arterial hypertension	723 (71.2)
Stroke	88 (8.7)
Tobacco use	
Former smoker	602 (59.3)
Active smoker	125 (12.3)
Women (n=428)	
Diabetes	251 (58.6)
Arterial hypertension	364 (85.0)
Stroke	53 (12.4)
Tobacco use	
Former smoker	38 (8.9)
Active smoker	21 (4.9)
Lifestyle	
Exercise (n=1388)	
No	914 (65.9)
Yes	418 (30.1)
Unknown	56 (4.0)
Lipid lowering diet (n=1361)	
No	397 (29.2)
Yes	964 (70.8)

IC indicates ischaemic cardiopathy; n, number of valid observations; SD, standard deviation.

TABLE 4. Lipid profile parameters (n=5256 visits)

	No. (%)
Total cholesterol (n=5231; Mean: 194.2 mg/dL; SD: 42.3)	
≤ 200 mg/dL	3239 (61.9)
200-240 mg/dL	1307 (25.0)
>240 mg/dL	685 (13.1)
HDL-C (n=5127; Mean: 48.2 mg/dL; SD: 12.7)	
≤ 40 mg/dL	1.576 (30.7)
40-60 mg/dL	2.774 (54.1)
>60 mg/dL	777 (15.2)
LDL-C (n=5,092; Mean: 116.2 mg/dL; SD: 33.9)	
≤ 70 mg/dL	292 (5.7)
70-100 mg/dL in non diabetics	916 (18.0)
70-100 mg/dL in diabetics	640 (12.6)
>100 mg/dL	3,244 (63.7)
Triglycerides (n=5115; Mean: 150.7 mg/dL; SD: 73.7)	
≤ 150 mg/dL	3,021 (59.1)
150-200 mg/dL	1,251 (24.5)
>200 mg/dL	843 (16.5)

N indicates number of valid observations; SD, standard deviation.

No significant association was found between TI and sex. However, when analysing this factor based on TI severity, there is an association: the percentage of high and very high TI is significantly ($P<.05$) higher in women (high TI: 35% in women and 27% in men; and very high TI: 34% in women and 26% in men).

We found a significant association between TI and physician's years of experience, and when stratifying by patient age, in young patients (<55), TI goes down as physician experience increases (Figure 2). In diabetics, TI is significantly higher in the LDL-C range of 70-100 mg/dL than with LDL-C >100 mg/dL (76.5% vs 34.6%).

On carrying out the logistical regression multivariate analysis and comparing it with the univariate analysis, (Table 6), we saw that the greater association with TI corresponded to the visits with levels of total cholesterol ≤200 mg/dL (with medication change criteria). Diabetes, that was a significant risk factor for the univariate TI analysis ($P<.001$), when adjusted taking into account lipid profile variables is no longer a risk factor ($P=.07$). High HDL-C levels and low total cholesterol values are shown to be risk factors for TI. A history of stroke, independent of diabetes, reduces TI. In the case of other variables that were significantly associated with TI in the univariate analysis, significance disappears when the multivariate model is adjusted, this is the case for: triglycerides, number of drugs, patient age, diet for dyslipidaemia, number of patients/week, courses on dyslipidaemia during the last 2 years, when the physician sets a value as a therapeutic

TABLE 5. Distribution of the Type of Therapeutic Inertia During the Visit According to LDL-C and Risk Factors (n=1636)

LDL-C, mg/dL	Risk Factors (RF)		
	Non smoker and non diabetic	Smoker or diabetic with no other RF	Smoker+HT or Diabetes+Smoker or Diabetes+HT
≥70-<100	NA	TI: 73 (4.5%)	High TI: 379 (23.2%)
≥100	TI: 609 (37.2%)	High TI: 103 (6.3%)	Very high TI: 472 (28.9%)

HT indicates hypertension; LDL-C, low density lipoproteins cholesterol; NA, not applicable (according to the definition of TI used); TI, therapeutic inertia.


Figure 2. Therapeutic inertia (TI) according to patients' age and physicians' years of experience. ns = not significant

target or considers there is undertreatment due to organisational aspects or fear of side effects.

With reference to aspects related to the cardiologist, a lower TI is related to years of experience, with the fact that the physician considers that the lack of protocols is the cause of undertreatment, with a greater attendance at congresses and with a greater number of patients with dyslipidaemia during consultations. In contrast, when the hours per year of training are at the work centre or when the physician considers that the percentage of patients who comply with treatment is greater, there is greater risk of TI (Table 6).

DISCUSSION

Our treatment indicators are better than those of the L-TAP study, that estimated that 82% of patients with dyslipidaemia and ischaemic cardiopathy did not have LDL-C values within the recommended therapeutic target values,[13] but were worse than those seen in another more recent study, also on ischaemic cardiopathy, that considered patients with LDL-C and HDL-C were over 50% and 80% respectively, outside recommended target values.[25]

The novelty of our study is that it confirms a high proportion of undertreatment associated with TI in the management of dyslipidaemia in the area of outpatient cardiology. These data are a cause for concern when many of the participating physicians (83%) recognise a priori, that there is undertreatment of dyslipidaemia and in their majority attend specific training courses.

Another aspect to be highlighted, is the global association of TI and cardiovascular risk. In two thirds of places TI can be considered high or very high. The GPC underline the need to tighten lipid control in patients at greater risk. However, in our study, diabetes adjusted to LDL-C values becomes a weak protective factor (P=.07), and the other traditional risk factors (hypertension, tobacco smoking, obesity, physical exercise) do not intervene in the decision to intensify treatment. In contrast, the finding that a history of stroke contributes to improve dyslipidaemia treatment is extremely interesting, this was supported by the recently published results of the ASCOT study.[26]

Although when considered as a whole, no association has been seen between TI and sex when analysing the type of TI, it has been found that high or

TABLE 6. Logistic Regression Adjusted Model. Dependent Variable: Therapeutic Inertia of the Visit (n=3824)

Variables in the Model	Raw Association (Univariate)		Adjusted Model	
	OR (95%CI)	P	OR (95% CI)	P
Total cholesterol				
≤ 200 mg/dL	8.1 (6.4–10.3)	<.001	6.5 (5.0-8.4)	<.001
200-240 mg/dL	2.7 (2.1–3.5)	<.001	2.8 (2.2-3.7)	<.001
>240 mg/dL	1		1	
HDL-C				
≤ 40 mg/dL	1		1	
40-60 mg/dL	1.6 (1.4-1.9)	<.001	1.5 (1.3–1.8)	<.001
>60 mg/dL	1.7 (1.4-2.1)	<.001	1.8 (1.4-2.3)	<.001
LDL-C				
70-100 mg/dL[a]	6.0 (5.1-7.5)	<.001	4.0 (3.2-5.0)	<.001
>100 mg/dL	1		1	
Treatment with statins				
Yes vs No	2.1 (1.6-2.7)	<.001	1.4 (1.0-1.9)	<.05
Diabetes				
Yes vs No	1.5 (1.3-1.7)	<.001	0.9 (0.7-1.0)	.070
Stroke				
Yes vs No	0.7 (0.5-0.9)	<.001	0.7 (0.6-0.9)	<.05
Years of dyslipidaemia treatment				
>5 vs ≤5	1.4 (1.2-1.5)	<.001	1.4 (1.2-1.5)	<.001
Physician's years of experience				
≤10	1.0		1.0	
>10-≤20	0.9 (0.8-1.1)	ns	0.7 (0.6-0.9)	<.01
>20	1.0 (0.9-1.2)	ns	0.8 (0.7-0.9)	<.05
Lack of protocols is a cause of undertreatment[b]				
Yes vs No	0.6 (0.5-0.7)	<.001	0.6 (0.4-0.7)	<.001
No of Congresses in the last 2 years				
>5 vs ≤5	.7 (0.6-0.8)	<0.001	0.7 (0.6-0.8)	<.001
Hours of training per year at own work centre				
0 to 9	1		1	
10 to 49	1.3 (1.1-1.5)	<.01	1.2 (0.9-1.5)	<.01
≥50	1.5 (1.2-1.9)	<.001	1.5 (1.2-1.9)	<.001
% of patients with dyslipidaemia[b]				
<25	1		1	
26 to 50	0.6 (0.5-0.8)	<.001	0.7 (0.5-0.8)	<.01
>50	0.6 (0.5-0.7)	<.001	0.8 (0.6-1.0)	.059
% if dyslipidaemic patients who comply with treatment[b]				
>50 vs ≤50	1.9 (1.5-2.4)	<0.001	1.9 (1.5-2.6)	<0.001

Variables outside the model: triglycerides, number of drugs, patient age, diet for dyslipidaemia, set values for therapeutic target, considers that there is undertreatment due to organisational aspects and fear of side effects, courses on dyslipidaemia in last 2 years, No of patients/week.
[a]This LDL-C value can only be a cause of TI in diabetic patients.
[b]Physicians' opinions.

very high TI is more frequent in women. This finding, confirms the fact that physicians underestimate or undertreat risk factors, which is in agreement with what has been described in relation to the differences seen between sexes in the management of risk factors and ischaemic cardiopathy itself.[27]

The association of selectively lower TI in young patients cared for by physicians with greater experience, we believe to be due to the fact that these physicians have a greater understanding of the chronic and recurrent nature of this disease. Length of time of lipid lowering treatment is a factor that,

in our study, is associated with TI, probably due to rejection to treatment changes on the part of the stable patient. Although it is also possible that there is "inertia" on the part of the physician to modify a treatment which proves to be effective over time.

According to our results the values of total cholesterol are considered more important than those of LDL-C when deciding not to change a treatment. Something similar occurs when HDL-C levels are above 40 mg/dL. These findings could be partly justified, by an estimation of sufficient validity of total cholesterol values to establish treatment,

and on the other hand, by the belief of a greater preventive capacity on the part of HDL-C than has been proven.

It is only logical to believe that hours of training correlate with knowledge and adherence to GPC. When analysing the attendance at congresses or a greater number of hours per year of training at the work centre, we saw that attending congresses reduced TI, in comparison with local training, which has an inverse effect to that expected. This finding could be explained by the fact that physicians with less TI who attend less training at their work centre, are those with greater experience, greater activity and care pressure, but with a greater attendance at congresses. In any case, the reason for this association is not clear.

Most of the physicians in this study recognise that dyslipidaemia in patients with ischaemic cardiopathy is undertreated, and it is their opinion that this undertreatment can be due to ignorance of the GPC, fear of medication side effects and, in great measure, care overload. However, we have assessed care pressure by means of the number of patients/week and have not found an association with TI, therefore, it is possible that it is a perception on the part of the physician and not a real cause of undertreatment. It is also noteworthy, that less than half of the physicians recognise that there is communication and coordination with primary care; which, in our opinion, should lead us to reflect on the organisational model and shows a route of action to improve control of these patients and probably of all chronic cardiovascular conditions.

However, we are sure that there are still factors that have not been considered in this study and that are a cause of TI. Organisational aspects such as duration of visit, lack of motivation or rejection of therapeutic changes by the patients who are stable among others, are involved in this complex and severe care problem. It would seem evident that the GPC alone do not modify clinical practice with sufficient speed to be appropriate and that strategies must be found to improve knowledge and facilitate care. We should take advantage of the support provided by new technologies as also the multidisciplinary role of care. We need support systems for the correct decisions (electronic and/or paper), population health education, reminder systems, coordination with primary care, and inclusion of these patients as chronic patients in nursing and clinical pharmacology protocols.[28-32]

Limitations of the Study

The sample of physicians was not randomly taken, but to minimise bias, we have used several measures: distribution in all communities, letter of invitation from the scientific society and choice of a retrospective design of consecutive patients (without possibility, therefore, of modifying their habitual practices or prescriptions). The data of our study do not disagree with those described in the literature with reference to lipid levels, treatment using different statins at a national level[33] and population risk factors such as chronic ischaemic cardiopathy[25,34] (as a low percentage of patients with ischaemic cardiopathy and recommended lipid levels according to the guidelines), which we consider supports the representativity of the sample analysed.

CONCLUSIONS

Our study confirms the high proportion of TI in the management of dyslipidaemia in outpatient cardiology.

When managing lipids in patients with coronary cardiopathy physicians ignore the existence of other cardiovascular risk factors. Even the presence of diabetes does not lead physicians to clearly and significantly change their therapeutic attitude.

The severity of TI in lipid management in patients with ischaemic cardiopathy is greater in women, and overall risk factors are under-estimated.

Physicians continue to be guided by total cholesterol levels or assume that HDL-C level means a preventative measure, and do not follow GPC recommendations when they decide to change treatments.

Only those physicians with greater professional experience closely adhere to GPC with younger patients. Attendance at different training activities improves GPC adhesion.

Cardiologists recognise the undertreatment of dyslipidaemia, and also that there is little communication with primary care in the follow-up of these patients.

REFERENCES

1. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135:825-34.
2. Andrade SE, Gurwitz JH, Field TS, Séller M, Majumdar SR, Reed G, et al. Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care. 2004;10:481-6.
3. Okonoufa EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47:345-51.
4. Salisbury C, Fahey T. Overcoming clinical inertia in the management of hypertension. CMAJ. 2006;174:1285-6.
5. Ziemer DC, Miller CD, Rhee MK, Doyle JP, Watkins C, Jr, Cook CB, et al. Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ. 2005;31: 564-71.

6. Shah BR, Hux JE, Laupacis A, Zinman B, van WC. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005;28:600-6.

7. Redón J, Coca A, Lázaro P, Aguilar MD, Cabañas M, Gil N, et al. Factors Associated With Therapeutic Inertia In Hypertension: Validation Of A Predictive Model. Journal of Hypertension (to be published).

8. Grant R, Adams AS, Trinacty CM, Zhang F, Kleinman K, Soumerai SB, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30:807-12.

9. Mendelson G, Aronow WS. Underutilization of measurement of serum low-density lipoprotein cholesterol levels and of lipid-lowering therapy in older patients with manifest atherosclerotic disease. J Am Geriatr Soc. 1998;46:1128-31.

10. Turner BJ, Hollenbeak CS, Weinwe M, Ten Have T, Tang SK. Effect of unrelated comorbid conditions on hypertension management. Ann Intern Med. 2008;148:578-86.

11. Kerr EA, Zikmund-Fisher BJ, Klamerus ML, Subramanian U, Horgan MM, Hofer TP. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med. 2008;148:717-27.

12. Fuke D, Hunt J, Siemienczuk J, Estoup M, Carroll M, Payne N, Touchette D. Cholesterol management of patients with diabetes in a primary care practice-based research network. Am J Manag Care. 2004;10:130-6.

13. Pearson TA, Laurora I, Chu H, Kafonck S. The Lipid Treatment Assesment Project (L-TAP). A multicenter survey to evaluate percentages of dyslipemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-67.

14. Willig JH, Jackson DA, Westfall AO, Allison J, Chang Pei-Wen, Raper J, et al. Clinical Inertia in the Management of Low-Density Lipoprotein Abnormalities in an HIV Clinic. HIV/AIDS CID. 2008;46:1315-8.

15. Abuful A, Gidron Y, Henkin Y. Physicians' attitudes toward preventive therapy for coronary artery disease: is there a gender bias? Clin Cardiol. 2005;28:389-93.

16. Rodondi N, Peng T, Karter AJ, Bauer DC, Vittinghoff E, Tang S, et al. Therapy modifications in response to poorly controlled hypertension, dyslipidemia and diabetes mellitus. Ann Intern Med. 2006;144:475-84.

17. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

18. Grundy SM, Cleeman JI, Bairey CN, Brewer HB, Clark LT, Hunninghake DB et al. NCEP Report: Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatmen Panel III Guidelines. Circulation 2004;110:227-39.

19. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering Medications at discharge in patients with acute myocardial infarction. Data from the National Registry of Myocardial Infarction 3. Circulation. 2001;103:38-44.

20. Goldberg KC, Melnyk SD, Simel DL. Overcoming Inertia: Improvement in Achieving Target Low-density Lipoprotein Cholesterol. Am J Manag Care. 2007;13:530-4.

21. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ. 2000;321:13225.

22. Martínez-Hernández AA, Aguilar-Leñero MJ, Rabadán Mengíbar M, Hernansanz-Iglesias F, González-Ramos J, Marín-Obáñez A. Prevención secundaria de cardiopatía isquémica a nivel lipídico en atención primaria Aragón. Estudio PRECIAR. Rev. Esp. Salud Pública. 2001;75:143-50.

23. García Ruiz FJ, Marín Ibáñez A, Pérez-Jiménez F, Pintó X, Nocea G, Ahumada C, Alemao E, Yin D; REALITY Study Group. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics. 2004;22 Suppl 3:1-12.

24. Medrano MJ, Pastor-Barriuso R, Boix R, del Barrio JL, Damián J, Álvarez R et al. Estudio ZACARIS. Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española. Rev Esp Cardiol. 2007;60:1250-6.

25. González-Juanatey JR, Alegría-Ezquerra E, Aznar-Costa J, Bertomeu-Martínez V, Franch-Nadal J, Palma-Gámiz JL. Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas. Rev Esp Cardiol. 2006;59:801-6.

26. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. The Lancet. 2005;366:895-906.

27. Aguilar MD, Lázaro P, Fitch K, Luengo S. Gender differences in clinical status at time of coronary revascularization in Spain. J Epidemiol & Community Health 2002;56:555-9.

28. Cabana MD, Rand CS, Powe NR Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65.

29. Roumie CL. Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Inter Med. 2006;145:165-75.

30. Davidson MH. Strategies to improve adult treatment Panel III Guideline Adherence and patient compliance. Am J Cardiol. 2002;89 Suppl :C8-22.

31. Afonso NM, Nassif G, Aranha AN, Delor B, Cardozo LJ. Low-density lipoprotein cholesterol goal attainment among high-risk patients: Does a combined intervention targeting patients and providers work? Am J Manag Care. 2006;12:589-94.

32. van Wyk JT, van Wikj MAM, Sturkenboom MCJM, Mosseveld M, Moorman PW, van der Lei J. Electronic alerts versus on-demand decision support to improve dyslipidemia treatment. A cluster randomized controlled trial. Circulation. 2008;117:371-8.

33. Centro de Información y Evaluación de Medicamentos y Productos Sanitarios de la Región de Murcia. Hipolipemiantes. Evaluación Farmacoterapéutica. 2007;1:1-8.

34. Waters DD, Brotons C, Chiang C, Ferrières J, Foody J, Jukema W, et al. Lipid Treatment Assesment Project 2. A multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120:28-34.